Pfizer
FDA Grants New Indication for Talzenna with Enzalutamide for HRR Gene-mutated mCRPC
The FDA approved Talzenna with enzalutamide for homologous recombination repair gene-mutated metastatic ...
JUNE 28, 2023
FDA Approves Zavzpret Nasal Spray to Treat Migraine
The FDA approved Zavzpret, the first calcitonin gene–related peptide receptor antagonist nasal spray, for the ...
MARCH 15, 2023
Prescribe Paxlovid, but Know the Risks
Paxlovid reduces hospitalizations and deaths from COVID-19, so clinicians should not avoid prescribing it for mild ...
JUNE 2, 2022
FDA Approves Pfizer Biosimilar to Rituxan
Rituximab-pvvr is a monoclonal antibody that works by targeting a protein called CD20, which is present on the ...
JULY 24, 2019
FDA Approves Bavencio With Inlyta for Patients With Advanced Renal Cell Carcinoma
Bavencio with Inlyta is the first FDA approval for an anti–PD-L1 therapy as part of a combination regimen for ...
MAY 16, 2019
FDA Approves Vyndaqel and Vyndamax for Rare Cardiac Condition
Transthyretin-mediated amyloidosis is a rare, life-threatening disease characterized by the buildup of abnormal ...
MAY 6, 2019
Trazimera, Biosimilar to Herceptin, Gains Approval
A new biosimilar was approved for Herceptin to treat HER2-overexpressing breast cancer and HER2-overexpressing ...
MARCH 12, 2019
FDA Approves Talzenna for gBRCAm HER2-Negative Breast Cancer
The FDA approved Talzenna, a poly(adenosine diphosphate–ribose) polymerase inhibitor, for patients with ...
OCTOBER 16, 2018
FDA Approves Nivestym, Second Biosimilar of Neupogen
The FDA approved Pfizer's Nivestym, a biosimilar of Neupogen for all eligible indications as the reference ...
JULY 23, 2018
Hospira Recalls Naloxone Product
Hospira issued a voluntary recall of one of its naloxone products because of it might contain loose particulate ...
JUNE 5, 2018
First Epoetin alfa Biosimilar Receives FDA Approval for Anemia
Retacrit is the first U.S. biosimilar erythropoiesis-stimulating agent (ESA). Although not listed as an ...
MAY 15, 2018
New Indication Granted for Bosutinib to Treat Newly Diagnosed Ph+ CML
Bosulif is now indicated for adults with newly diagnosed chronic phase, Philadelphia chromosome–positive ...
DECEMBER 20, 2017
